Market Context — Why This Technology, Why Now

Global healthcare systems face mounting pressure to adapt to evolving medical treatments and unpredictable emergencies. The rise of advanced nuclear medicine therapies necessitates specialized, yet flexible, infrastructure. Simultaneously, geopolitical instability and the increasing frequency of natural disasters highlight the critical need for rapidly deployable medical solutions that minimize disruption to existing facilities and ensure continuous care for affected populations.

Key Competitive Advantages
01

Reduces deployment and removal time by up to 70% compared to conventional fixed facilities, enabling rapid response to emergencies or temporary demand.

02

Optimizes safety management for alpha emitters by specializing in alpha-emitting radionuclides and their decay products, avoiding excessive capital investment.

03

Minimizes impact on existing facilities by functioning as an independent, portable unit, eliminating the need for extensive renovations and shortening lead times.

Market Opportunity
🏥 Nuclear Medicine Treatment Facilities
$200M–$2B globally (AI est.)
Demand for specialized radiation controlled areas is surging due to the development and proliferation of new treatments like Targeted Alpha Therapy (TAT) using alpha-emitting radionuclides.
Nuclear medicine clinics Oncology treatment centers Medical device manufacturers for radiotherapy
🚑 Disaster Medical Care & Emergency Response
$50M–$650M globally (AI est.)
The risk of existing medical infrastructure failing during large-scale disasters or pandemics is increasing, driving the need for rapidly deployable and removable temporary medical facilities.
Emergency response organizations Disaster relief agencies Mobile hospital unit providers
🧪 Research & Development Institutions
$50M–$650M globally (AI est.)
Active research and development in new radioactive isotope tracers and radiopharmaceuticals requires safe and flexible environments for handling radioactive materials.
Pharmaceutical R&D labs University research hospitals Biotech companies developing radiopharmaceuticals
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a portable administration facility unit specifically designed for alpha-emitting radionuclides, featuring a controlled area and an internal patient bed. It was granted after overcoming two office actions, demonstrating strong novelty and inventiveness against four prior art references, suggesting a robust and difficult-to-invalidate right.

Competitive White Space

This patent primarily covers portable units for alpha-emitting radionuclides. White space exists in developing integrated remote operation systems, advanced waste management solutions, or units for other radiation types (e.g., beta or gamma emitters).

Economic Impact
~$165K/year estimated operational cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

A single deployment and removal could save ~$230K (AI est.) compared to conventional fixed radiation controlled areas (e.g., ~$330K (AI est.) for construction/demolition vs. ~$100K (AI est.) for unit deployment/removal). Additionally, optimized management for alpha emitters could reduce annual personnel costs by ~10% (equivalent to ~$16K/year (AI est.) for 3 staff at ~$53K/person (AI est.)). Combined with increased operational efficiency from flexible redeployment, this could lead to annual operational cost savings of ~$165K (AI est.) per facility.

Speed to Market
4× faster than in-house development
This technology's concept as a portable unit, with a clearly defined radiation controlled area and patient bed configuration, is well-established. This significantly shortens the design and construction period compared to greenfield development. Combined with existing logistics infrastructure, rapid deployment is possible, potentially reducing time to market by approximately 3 years.
Competitive Positioning

X: Deployment Flexibility & Speed
Y: Specialization & Safety

Business Models & Applications
🤝 Licensing Model
License the manufacturing and sales rights of this technology to an adopting company, generating royalty income. This model leverages the licensee's manufacturing and distribution channels for rapid market penetration.
🗓️ Unit Rental Service
Offer this administration facility unit as a rental service for disaster relief or short-term research projects. This model addresses customer needs for lower initial investment and expands revenue opportunities.
💡 Design & Consulting Services
Provide customized design services tailored to specific licensee needs, along with consulting on radiation management protocols, offering a high-value solution.
Adjacent Application Opportunities
🚧 Construction & Infrastructure
Modular Radiation Isolation Wards
Leveraging the portable nature of this technology, it could be repurposed as modular radiation isolation wards for rapid deployment and removal within existing hospital grounds. This offers flexible solutions for infectious disease control or temporary bed shortages.
🛡️ Defense & Security
Mobile Nuclear Material Detection & Decontamination Stations
Applying the radioactive nuclide management technology, it could be developed into mobile stations for nuclear material detection and decontamination. This has the potential to significantly enhance initial response capabilities for counter-terrorism or accident scenarios.
🚀 Space Exploration
Lunar/Mars Base Radiation Protection Shelters
To protect astronauts from radiation exposure in space, the shielding and management concepts of this technology could be adapted for lightweight, deployable radiation protection shelters for lunar or Martian bases.
Integration Roadmap — Estimated 12-Month Deployment
Phase 1: Technical Feasibility & Requirements Definition
Duration: 3 months
Evaluate the compatibility of this technology with the licensee's existing infrastructure and operational systems, then define specific implementation requirements. Establish initial design adjustments and regulatory compliance strategies.
Phase 2: Prototype Development & Validation
Duration: 6 months
Develop a demonstrable prototype based on the defined requirements and verify key performance metrics such as radiation shielding, portability, and setup/removal times. Identify and address operational challenges during this stage.
Phase 3: Production Deployment & Operational Optimization
Duration: 3 months
Deploy the final product, incorporating validation test results, and conduct performance evaluation and optimization in a real operational environment. Complete employee training and establish maintenance protocols during this phase.
Technical Feasibility
This technology is structured as a 'portable' 'unit,' allowing for flexible integration without extensive modifications to existing buildings or infrastructure. The patent claims describe an integrated structure of a radiation controlled area and a patient bed, which is highly likely achievable by assembling pre-manufactured modules on-site. By combining with general construction techniques, complex specialized work can be avoided, indicating a low technical barrier to adoption.
Success Scenario
Upon adopting this technology, licensees could significantly reduce the lead time for constructing or renovating conventional radiation controlled areas from several months to a few weeks. This would enable flexible and rapid deployment of patient beds in response to surging demand for nuclear medicine treatments or emergency medical needs, potentially expanding patient acceptance capacity by up to 1.5 times. Easy removal when no longer needed also allows for efficient land use and flexible business portfolio adjustments.
Patent Record
APPLICATION NO.
特願2020-025584
REGISTRATION NO.
7509400
FILING DATE
2020/02/18
GRANT DATE
2024/06/24
EXPIRATION DATE
2040/02/18
PATENT HOLDER
国立研究開発法人量子科学技術研究開発機構
Examination History
2022年10月21日
出願審査請求書
2023年09月05日
拒絶理由通知書
2023年10月25日
意見書
2023年10月25日
手続補正書（自発・内容）
2023年12月12日
拒絶理由通知書
2024年04月08日
手続補正書（自発・内容）
2024年04月08日
意見書
2024年06月04日
特許査定